Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme

HealthTech approach

HealthTech approach

Advice programme

Area of interest

Showing 211 to 220 of 1523

TitleReference numberPublishedLast updated
Secukinumab for treating moderate to severe hidradenitis suppurativaTA935
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)TA936
Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolismHTG705
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)TA933
Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptomsTA934
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal)TA932
Percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosisHTG704
Zanubrutinib for treating chronic lymphocytic leukaemiaTA931
Transient loss of consciousness ('blackouts') in over 16sCG109
Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessmentHTG701

Results per page

  1. 10
  2. 25
  3. 50
  4. All